In the dynamic landscape of antibody research and therapeutics, having a diverse array of purification methods is essential. At Evitria AG, we recognize the need for flexibility to meet various project requirements. Let’s delve into our updated purification services.
Dr. Desmond Schofield, has been appointed Chief Business Officer as of 1st January 2024.
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.
Delivering material with the same quality at every scale, and with several years in between campaigns, enabled our client to rapidly move through development stages without having to undertake difficult troubleshooting activities or worry about their material quality.
The design of your antibody sequence is the single most important step in your therapeutic development journey. Weak binding, off-target effects, and insufficient activity can all improve via sequence engineering.
At evitria, we are specialized in transient transfection of CHO cells to produce recombinant antibodies. Find out more about our approach in this article.